Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis

Combined Topical Corticosteroid and Topical Cyclosporine-A for Management of COVID-19 Keratoconjunctivitis; a Pilot Study

To explore the feasibility of combined topical corticosteroid and topical cyclosporine-A in COVID-19 patients with acute keratoconjunctivitis.

COVID-19 patients presenting with acute keratoconjunctivitis will be treated with Topical 1% prednisolone acetate fourTimes daily for 7 days as initial treatment, non-preserved artificial tears four times daily and cyclosporin A 0.5% four times daily .

Twelve patients with COVID-19 Keratoconjunctivitis will be enrolled in this open-label study. Symptoms and findings of the patients before and after treatment were recorded.

Inclusion Criteria:

• COVID-19 Patients with keratoconjunctivitis

Exclusion Criteria:

• associated ocular pathology or disease
• other causes of keratoconjunctivitis for example allergic or herpetic